Works by Stella, Philip J


Results: 18
    1
    2
    3

    Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.

    Published in:
    2017
    By:
    • Smith II, John W.;
    • Buyse, Marc E.;
    • Rastogi, Priya;
    • Geyer Jr., Charles E.;
    • Jacobs, Samuel A.;
    • Patocskai, Erica J.;
    • Robidoux, André;
    • Conlin, Alison K.;
    • Ansari, Bilal;
    • Keogh, George P.;
    • Stella, Philip J.;
    • Gross, Howard M.;
    • Lord, Raymond S.;
    • Polikoff, Jonathan A.;
    • Mauquoi, Celine;
    • Mamounas, Eleftherios P.;
    • Swain, Sandra M.;
    • Wolmark, Norman;
    • Smith, John W 2nd;
    • Geyer, Charles E Jr
    Publication type:
    journal article
    4

    Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial.

    Published in:
    2012
    By:
    • Tan WW;
    • Allred JB;
    • Salim M;
    • Flynn P;
    • Fishkin PA;
    • Stella PJ;
    • Wiesenfeld M;
    • Bernath AM;
    • Fitch TR;
    • Perez EA;
    • Tan, Winston W;
    • Allred, Jacob B;
    • Salim, Muhammad;
    • Flynn, Patrick;
    • Fishkin, Paul A S;
    • Stella, Philip J;
    • Wiesenfeld, Martin;
    • Bernath, Albert M;
    • Fitch, Tom R;
    • Perez, Edith A
    Publication type:
    journal article
    5
    6
    7
    9
    10
    11
    12
    13

    Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.

    Published in:
    Oncologist, 2022, v. 27, n. 4, p. 292, doi. 10.1093/oncolo/oyab025
    By:
    • Lipsyc-Sharf, Marla;
    • Ou, Fang-Shu;
    • Yurgelun, Matthew B;
    • Rubinson, Douglas A;
    • Schrag, Deborah;
    • Dakhil, Shaker R;
    • Stella, Philip J;
    • Weckstein, Douglas J;
    • Wender, Donald B;
    • Faggen, Meredith;
    • Zemla, Tyler J;
    • Heying, Erica N;
    • Schuetz, Samantha R;
    • Noble, Stephanie;
    • Meyerhardt, Jeffrey A;
    • Bekaii-Saab, Tanios;
    • Fuchs, Charles S;
    • Ng, Kimmie
    Publication type:
    Article
    14
    15
    16
    17

    Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer.

    Published in:
    Breast Cancer Research & Treatment, 2022, v. 192, n. 1, p. 153, doi. 10.1007/s10549-021-06475-2
    By:
    • Ganz, Patricia A.;
    • Bandos, Hanna;
    • Geyer Jr., Charles E.;
    • Robidoux, André;
    • Paterson, Alexander H. G.;
    • Polikoff, Jonathan;
    • Baez-Diaz, Luis;
    • Brufsky, Adam M.;
    • Fehrenbacher, Louis;
    • Parsons, Ann W.;
    • Ward, Patrick J.;
    • Provencher, Louise;
    • Hamm, John T.;
    • Stella, Philip J.;
    • Carolla, Robert L.;
    • Margolese, Richard G.;
    • Shibata, Henry R.;
    • Perez, Edith A.;
    • Wolmark, Norman
    Publication type:
    Article
    18